Terms: = Lung cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
126 results:
1. Real-World treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
2. Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell lung cancer Patients: A Field Synopsis and Meta-Analysis.
Sito H; Sharzehan MAK; Islam MA; Tan SC
Br J Biomed Sci; 2024; 81():11835. PubMed ID: 38450253
[No Abstract] [Full Text] [Related]
3. Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking.
Wang M; Li R; Bai M; Zhou X
Medicine (Baltimore); 2024 Mar; 103(9):e37218. PubMed ID: 38428907
[TBL] [Abstract] [Full Text] [Related]
4. Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
Sebastian M; Eberhardt WEE; von der Heyde E; Dörfel S; Wiegand J; Schiefer C; Losem C; Jänicke M; Fleitz A; Zacharias S; Kaiser-Osterhues A; Hipper A; Dietel C; Bleckmann A; Benkelmann R; Boesche M; Grah C; Müller A; Griesinger F; Thomas M;
Int J Cancer; 2024 Jun; 154(11):1967-1978. PubMed ID: 38329180
[TBL] [Abstract] [Full Text] [Related]
5. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
[TBL] [Abstract] [Full Text] [Related]
6. Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model.
Chen Z; Zhuang J; Liu M; Xu X; Liu Y; Yang S; Xie J; Lin N; Lai F; He F
BMC Pulm Med; 2024 Jan; 24(1):36. PubMed ID: 38233781
[TBL] [Abstract] [Full Text] [Related]
7. Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC.
Lee M; Liu J; Miao E; Wang S; Zhang F; Wei J; Chung J; Xue X; Halmos B; Hosgood HD; Cheng H
J Natl Compr Canc Netw; 2023 Dec; 21(12):1269-1280.e5. PubMed ID: 38081123
[TBL] [Abstract] [Full Text] [Related]
8. Impact of rapid on-site evaluation in expediting the fast investigative lung cancer pathway.
Fowell A; Khan K
Cytopathology; 2024 Mar; 35(2):250-255. PubMed ID: 38054566
[TBL] [Abstract] [Full Text] [Related]
9. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract] [Full Text] [Related]
10. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.
Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M
J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291
[TBL] [Abstract] [Full Text] [Related]
11. Real-World Experience in treatment of Patients with Non-Small-Cell lung cancer with BRAF or cMET Exon 14 Skipping Mutations.
Janzic U; Shalata W; Szymczak K; Dziadziuszko R; Jakopovic M; Mountzios G; Płużański A; Araujo A; Charpidou A; Agbarya A
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629023
[TBL] [Abstract] [Full Text] [Related]
12. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract] [Full Text] [Related]
13. Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of
Wu WY; Jiao X; Song WX; Wu P; Xiao PQ; Huang XF; Wang K; Zhan SF
Front Endocrinol (Lausanne); 2023; 14():1187882. PubMed ID: 37347115
[TBL] [Abstract] [Full Text] [Related]
14. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.
Zhou Q; Zhang HL; Jiang LY; Shi YK; Chen Y; Yu JM; Zhou CC; He Y; Hu YP; Liang ZA; Pan YY; Zhuo WL; Song Y; Wu G; Chen GY; Lu Y; Zhang CY; Zhang YP; Cheng Y; Lu S; Wang CL; Zhou JY; Liu YP; He JX; Wang J; Wu YL
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10771-10780. PubMed ID: 37316692
[TBL] [Abstract] [Full Text] [Related]
15. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract] [Full Text] [Related]
16. Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Fei Jin Sheng Formula in the treatment of lung cancer.
Zhang YC; Gao WC; Chen WJ; Pang DX; Mo DY; Yang M
Curr Pharm Des; 2023; 29(14):1121-1134. PubMed ID: 37138492
[TBL] [Abstract] [Full Text] [Related]
17. Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview.
Lasala R; Zovi A; Isgrò V; Romagnoli A; Musicco F; Santoleri F
Curr Med Res Opin; 2023 Dec; 39(12):1603-1612. PubMed ID: 36932463
[TBL] [Abstract] [Full Text] [Related]
18. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell lung cancer Harboring MET Exon 14 Skipping.
Yang M; Vioix H; Hook ES; Hatswell AJ; Batteson RL; Gaumond BR; O'Brate A; Popat S; Paik PK
Value Health; 2023 Aug; 26(8):1155-1163. PubMed ID: 36805576
[TBL] [Abstract] [Full Text] [Related]
19. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema P; Cho BC; Freitas H; Provencio M; Chen YM; Kim SW; Wu YL; Passaro A; Martin C; Tiseo M; Chang GC; Park K; Solomon B; Burghuber O; Laskin J; Wang Z; Lee SY; Hu Y; Vansteenkiste J; Zhang HL; Hanrahan E; Geldart T; Taylor R; Servidio L; Li J; Marinis F
Future Oncol; 2023 Jan; 19(1):61-75. PubMed ID: 36656302
[TBL] [Abstract] [Full Text] [Related]
20. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
Liu W; Zhang Q; Zhang T; Li L; Xu C
World J Surg Oncol; 2022 Oct; 20(1):333. PubMed ID: 36192730
[TBL] [Abstract] [Full Text] [Related]
[Next]
